Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Breast Cancer

Free Subscription 12.04.2021 1 AJR Am J Roentgenol 1 Am J Surg 11 Ann Surg Oncol 5 Anticancer Res 5 BMC Cancer 3 Br J Cancer 7 Breast Cancer 2 Breast Cancer (Auckl) 1 Breast Cancer (Dove Med Press) 1 Breast Cancer Res 10 Breast Cancer Res Treat 1 Cancer 1 Cancer Chemother Pharmacol 5 Cancer Epidemiol Biomarkers Prev 2 Cancer Lett 2 Cancer Res 4 Clin Breast Cancer 2 Clin Cancer Res 1 Exp Cell Res 1 Gene 2 Histopathology 2 Int J Cancer 6 Int J Radiat Oncol Biol Phys 3 J Clin Oncol 10 J Natl Cancer Inst 1 J Pathol 1 Lancet 1 NPJ Breast Cancer 1 Oncogene 1 Oncology (Williston Park) 3 PLoS One 2 Radiol Imaging Cancer 2 Radiology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. BALLEYGUIER C
   Editorial Comment on "Mixed-methods study to predict upstaging of DCIS to invasive disease on mammography".
   AJR Am J Roentgenol. 2020 Sep 2. doi: 10.2214/AJR.20.24467.
   PubMed        
   
   

   
   Am J Surg

2. KAPUR H, Warburton R, Pao JS, Dingee C, et al
   Decreasing contralateral prophylactic mastectomy rates in average-risk women with unilateral breast cancer.
   Am J Surg. 2021 Mar 24. pii: S0002-9610(21)00175.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

3. WEISS A, Campbell J, Ballman KV, Sikov WM, et al
   Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance).
   Ann Surg Oncol. 2021 Apr 5. pii: 10.1245/s10434-021-09897.
   PubMed         Abstract available
   
   
4. MCKEVITT E, Cheifetz R, DeVries K, Laws A, et al
   Sentinel Node Biopsy Should Not be Routine in Older Patients with ER-Positive HER2-Negative Breast Cancer Who Are Willing and Able to Take Hormone Therapy.
   Ann Surg Oncol. 2021 Apr 5. pii: 10.1245/s10434-021-09839.
   PubMed         Abstract available
   
   
5. GOMMERS JJJ, Duijm LEM, Bult P, Strobbe LJA, et al
   The Impact of Preoperative Breast MRI on Surgical Margin Status in Breast Cancer Patients Recalled at Biennial Screening Mammography: An Observational Cohort Study.
   Ann Surg Oncol. 2021 Apr 1. pii: 10.1245/s10434-021-09868.
   PubMed         Abstract available
   
   
6. EGAN KG, De Souza M, Muenks E, Nazir N, et al
   Opioid Consumption Following Breast Surgery Decreases with a Brief Educational Intervention: A Randomized, Controlled Trial.
   Ann Surg Oncol. 2020;27:3156-3162.
   PubMed         Abstract available
   
   
7. KEIM-MALPASS J, Anderson RT, Balkrishnan R, Desai RP, et al
   Evaluating the Long-Term Impact of a Cooperative Group Trial on Radiation Use and Adjuvant Endocrine Therapy Adherence Among Older Women.
   Ann Surg Oncol. 2020;27:3458-3465.
   PubMed         Abstract available
   
   
8. PYFER BJ, Jonczyk M, Jean J, Graham RA, et al
   Analysis of Surgical Trends for Axillary Lymph Node Management in Patients with Ductal Carcinoma In Situ Using the NSQIP Database: Are We Following National Guidelines?
   Ann Surg Oncol. 2020;27:3448-3455.
   PubMed         Abstract available
   
   
9. O'NEILL AC, Yang D, Roy M, Sebastiampillai S, et al
   Development and Evaluation of a Machine Learning Prediction Model for Flap Failure in Microvascular Breast Reconstruction.
   Ann Surg Oncol. 2020;27:3466-3475.
   PubMed         Abstract available
   
   
10. CAO L, Hue JJ, Freyvogel M, Li P, et al
    Despite Equivalent Outcomes, Men Receive Neoadjuvant Chemotherapy Less Often Than Women for Lymph Node-Positive Breast Cancer.
    Ann Surg Oncol. 2021 Apr 6. pii: 10.1245/s10434-021-09857.
    PubMed         Abstract available
    
    
11. CERVERA-BONILLA S, Rodriguez-Ossa P, Vallejo-Ortega M, Osorio-Ruiz A, et al
    Evaluation of the AJCC Eighth-Edition Prognostic Staging System for Breast Cancer in a Latin American Cohort.
    Ann Surg Oncol. 2021 Apr 8. pii: 10.1245/s10434-021-09907.
    PubMed         Abstract available
    
    
12. CERVERA-BONILLA S, Guzman-Abisaab L, Rodriguez-Ossa P
    ASO Author Reflections: Evaluation of the 8th AJCC Prognostic Staging System for Breast Cancer in a Latin American Cohort.
    Ann Surg Oncol. 2021 Apr 9. pii: 10.1245/s10434-021-09959.
    PubMed        
    
    
13. LIM DW, Retrouvey H, Kerrebijn I, Butler K, et al
    Longitudinal Study of Psychosocial Outcomes Following Surgery in Women with Unilateral Nonhereditary Breast Cancer.
    Ann Surg Oncol. 2021 Apr 5. pii: 10.1245/s10434-021-09928.
    PubMed         Abstract available
    
    

    
    Anticancer Res

14. JOSEPH WJ, Bustos SS, Losee JE, Rubin JP, et al
    The Impact of the COVID-19 Pandemic on Breast Reconstruction Practices in the United States.
    Anticancer Res. 2021;41:1903-1908.
    PubMed         Abstract available
    
    
15. VANNI G, Materazzo M, Pellicciaro M, Amir S, et al
    Breast Textured Implants Determine Early T-helper Impairment: BIAL2.20 Study.
    Anticancer Res. 2021;41:2123-2132.
    PubMed         Abstract available
    
    
16. SASAKI R, Horimoto Y, Yanai Y, Kurisaki-Arakawa A, et al
    Molecular Characteristics of Lymphocyte-predominant Triple-negative Breast Cancer.
    Anticancer Res. 2021;41:2133-2140.
    PubMed         Abstract available
    
    
17. HAYASHI K, Tamura M, Nagasaki E, Yoshii Y, et al
    A Retrospective Analysis of Perioperative Chemotherapy and Coronavirus Disease in Patients With Breast Cancer.
    Anticancer Res. 2021;41:2193-2195.
    PubMed         Abstract available
    
    
18. RIGAKOS G, Razis E, Koliou GA, Oikonomopoulos G, et al
    Evaluation of the Role of p95 HER2 Isoform in Trastuzumab Efficacy in Metastatic Breast Cancer.
    Anticancer Res. 2021;41:1793-1802.
    PubMed         Abstract available
    
    

    
    BMC Cancer

19. LIU Z, Liu J, Liu R, Xue M, et al
    Downregulated ZNF132 predicts unfavorable outcomes in breast Cancer via Hypermethylation modification.
    BMC Cancer. 2021;21:367.
    PubMed         Abstract available
    
    
20. LIANG G, Ma W, Zhao Y, Liu E, et al
    Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters.
    BMC Cancer. 2021;21:362.
    PubMed         Abstract available
    
    
21. LV R, Yang G, Huang Y, Wang Y, et al
    Dosimetric effects of supine immobilization devices on the skin in intensity-modulated radiation therapy for breast cancer: a retrospective study.
    BMC Cancer. 2021;21:384.
    PubMed         Abstract available
    
    
22. REECE JC, Neal EFG, Nguyen P, McIntosh JG, et al
    Delayed or failure to follow-up abnormal breast cancer screening mammograms in primary care: a systematic review.
    BMC Cancer. 2021;21:373.
    PubMed         Abstract available
    
    
23. CABIOGLU N, Onder S, Oner G, Karatay H, et al
    TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer.
    BMC Cancer. 2021;21:357.
    PubMed         Abstract available
    
    

    
    Br J Cancer

24. LUOND F, Tiede S, Christofori G
    Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression.
    Br J Cancer. 2021 Apr 6. pii: 10.1038/s41416-021-01328.
    PubMed         Abstract available
    
    
25. BINES J, Clark E, Barton C, Restuccia E, et al
    Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer.
    Br J Cancer. 2021 Apr 7. pii: 10.1038/s41416-021-01323.
    PubMed         Abstract available
    
    
26. AMERATUNGA M, Brana I, Bono P, Postel-Vinay S, et al
    First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Br J Cancer. 2020;123:1730-1736.
    PubMed         Abstract available
    
    

    
    Breast Cancer

27. FUTAMURA M, Oba M, Masuda N, Bando H, et al
    Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study).
    Breast Cancer. 2021 Apr 3. pii: 10.1007/s12282-021-01238.
    PubMed         Abstract available
    
    
28. INOUE K, Masuda N, Iwata H, Takahashi M, et al
    Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy.
    Breast Cancer. 2021 Apr 1. pii: 10.1007/s12282-021-01239.
    PubMed         Abstract available
    
    
29. SONG C, Lowe VJ, Lee S
    Inhibition of Cdc20 suppresses the metastasis in triple negative breast cancer (TNBC).
    Breast Cancer. 2021 Apr 3. pii: 10.1007/s12282-021-01242.
    PubMed         Abstract available
    
    
30. ZHANG J, Tian Q, Zhang M, Wang H, et al
    Immune-related biomarkers in triple-negative breast cancer.
    Breast Cancer. 2021 Apr 9. pii: 10.1007/s12282-021-01247.
    PubMed         Abstract available
    
    
31. PAPPOT H, Baeksted CW, Nissen A, Knoop A, et al
    Clinical effects of assessing electronic patient-reported outcomes monitoring symptomatic toxicities during breast cancer therapy: a nationwide and population-based study.
    Breast Cancer. 2021 Apr 9. pii: 10.1007/s12282-021-01244.
    PubMed         Abstract available
    
    
32. TAKADA M, Tanaka G, Hashimoto H, Hirai Y, et al
    Practical approach to prevent COVID-19 infection at breast cancer screening.
    Breast Cancer. 2021 Apr 2. pii: 10.1007/s12282-021-01235.
    PubMed         Abstract available
    
    
33. KONISHI T, Fujiogi M, Michihata N, Morita K, et al
    Comparisons of postoperative outcomes after breast cancer surgery in patients with and without renal replacement therapy: a matched-pair cohort study using a Japanese nationwide inpatient database.
    Breast Cancer. 2021 Apr 10. pii: 10.1007/s12282-021-01248.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Auckl)

34. HUSSEIN O, El-Ghitany EM, Omran M, Matariek G, et al
    High Seroprevalence of Hepatitis C Virus Antibody in Breast Cancer Patients in Egypt.
    Breast Cancer (Auckl). 2021;15:11782234211002499.
    PubMed         Abstract available
    
    
35. CIPRIANO E, Mesquita A
    Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer.
    Breast Cancer (Auckl). 2021;15:11782234211002491.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

36. HYDER T, Bhattacharya S, Gade K, Nasrazadani A, et al
    Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer.
    Breast Cancer (Dove Med Press). 2021;13:199-211.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

37. WU AH, Franke AA, Wilkens LR, Tseng C, et al
    Urinary phthalate exposures and risk of breast cancer: the Multiethnic Cohort study.
    Breast Cancer Res. 2021;23:44.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

38. MCSORLEY LM, Tharmabala M, Al Rahbi F, McSorley K, et al
    Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland.
    Breast Cancer Res Treat. 2021 Apr 9. pii: 10.1007/s10549-021-06211.
    PubMed         Abstract available
    
    
39. HOPSON MB, Lee S, Accordino M, Trivedi M, et al
    Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer.
    Breast Cancer Res Treat. 2021 Apr 10. pii: 10.1007/s10549-021-06210.
    PubMed         Abstract available
    
    
40. KEELAN S, Heeney A, Downey E, Hegarty A, et al
    Breast cancer patients with a negative axillary ultrasound may have clinically significant nodal metastasis.
    Breast Cancer Res Treat. 2021 Apr 10. pii: 10.1007/s10549-021-06194.
    PubMed         Abstract available
    
    
41. KRISTENSEN KB, Thomsen IMN, Berg T, Kodahl AR, et al
    Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2- metastatic breast cancer.
    Breast Cancer Res Treat. 2021 Apr 10. pii: 10.1007/s10549-021-06215.
    PubMed         Abstract available
    
    
42. JOHNSON AE, Coopey SB, Spring LM, Horick NK, et al
    Management and outcomes of men diagnosed with primary breast cancer.
    Breast Cancer Res Treat. 2021 Apr 8. pii: 10.1007/s10549-021-06174.
    PubMed         Abstract available
    
    
43. CHALASANI P, Farr K, Wu V, Jenkins I, et al
    Single arm, phase two study of low-dose metronomic eribulin in metastatic breast cancer.
    Breast Cancer Res Treat. 2021 Apr 2. pii: 10.1007/s10549-021-06175.
    PubMed         Abstract available
    
    
44. TURBOW SD, White MC, Breslau ES, Sabatino SA, et al
    Correction to: Mammography use and breast cancer incidence among older U.S. women.
    Breast Cancer Res Treat. 2021 Apr 5. pii: 10.1007/s10549-021-06212.
    PubMed        
    
    
45. BATTISTI NML, Andres MS, Lee KA, Ramalingam S, et al
    Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer.
    Breast Cancer Res Treat. 2021 Apr 5. pii: 10.1007/s10549-021-06192.
    PubMed         Abstract available
    
    
46. CHETRIT A, Ben-Avraham S, Mandelzweig L, Amitai T, et al
    Breast cancer survivors: physical and mental quality of life 10 years following diagnosis, a case-control study.
    Breast Cancer Res Treat. 2021 Apr 5. pii: 10.1007/s10549-021-06156.
    PubMed         Abstract available
    
    
47. SUTTON AL, Felix AS, Bandyopadhyay D, Retnam R, et al
    Cardioprotective medication use in Black and white breast cancer survivors.
    Breast Cancer Res Treat. 2021 Apr 2. pii: 10.1007/s10549-021-06202.
    PubMed         Abstract available
    
    

    
    Cancer

48. STANGL S, Rauch S, Rauh J, Meyer M, et al
    Disparities in accessibility to evidence-based breast cancer care facilities by rural and urban areas in Bavaria, Germany.
    Cancer. 2021 Apr 7. doi: 10.1002/cncr.33493.
    PubMed         Abstract available
    
    

    
    Cancer Chemother Pharmacol

49. XU B, Li H, Zhang Q, Sun W, et al
    Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women.
    Cancer Chemother Pharmacol. 2021 Apr 9. pii: 10.1007/s00280-021-04263.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

50. GABRIEL E, Brockman TA, Albertie M, Balls-Berry J, et al
    Neighborhood-Level Redlining and Lending Bias Are Associated with Breast Cancer Mortality in a Large and Diverse Metropolitan Area-Letter.
    Cancer Epidemiol Biomarkers Prev. 2021;30:799.
    PubMed        
    
    
51. TEHRANIFAR P, Wei Y, Terry MB
    Less Is More-Ways to Move Forward for Improved Breast Cancer Risk Stratification.
    Cancer Epidemiol Biomarkers Prev. 2021;30:587-589.
    PubMed         Abstract available
    
    
52. HENG YJ, Kensler KH, Baker GM, Collins LC, et al
    TDLU Involution and Breast Cancer Risk-Reply.
    Cancer Epidemiol Biomarkers Prev. 2021;30:798.
    PubMed        
    
    
53. COLLIN LJ, McCullough LE
    Redlining, Lending Bias, and Breast Cancer Mortality-Reply.
    Cancer Epidemiol Biomarkers Prev. 2021;30:800.
    PubMed        
    
    
54. DEGNIM AC, Radisky DC, Vachon CM, Sherman ME, et al
    Automated Quantitative Measures of Terminal Duct Lobular Unit Involution and Breast Cancer Risk-Letter.
    Cancer Epidemiol Biomarkers Prev. 2021;30:797.
    PubMed        
    
    

    
    Cancer Lett

55. KAUL K, Misri S, Ramaswamy B, Ganju RK, et al
    Contribution of the tumor and obese microenvironment to triple negative breast cancer.
    Cancer Lett. 2021 Mar 30. pii: S0304-3835(21)00141.
    PubMed         Abstract available
    
    
56. WANG CJ, Li D, Danielson JA, Zhang EH, et al
    Proton pump inhibitors suppress DNA damage repair and sensitize treatment resistance in breast cancer by targeting fatty acid synthase.
    Cancer Lett. 2021 Apr 1. pii: S0304-3835(21)00149.
    PubMed         Abstract available
    
    

    
    Cancer Res

57. CHEN F, Chen Z, Guan T, Zhou Y, et al
    N6-methyladenosine regulates mRNA stability and translation efficiency of KRT7 to promote breast cancer lung metastasis.
    Cancer Res. 2021 Apr 1. pii: 0008-5472.CAN-20-3779.
    PubMed         Abstract available
    
    
58. ZHENG W, Ranoa DRE, Huang X, Hou Y, et al
    RIG-I-Like Receptor LGP2 Is Required for Tumor Control by Radiotherapy.
    Cancer Res. 2020;80:5633-5641.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

59. JOY AA, Vos LJ, Pituskin E, Cook SF, et al
    Uridine Glucuronosyltransferase 2B7 Polymorphism-Based Pharmacogenetic Dosing of Epirubicin in FEC Chemotherapy for Early-Stage Breast Cancer.
    Clin Breast Cancer. 2021 Mar 6. pii: S1526-8209(21)00056.
    PubMed         Abstract available
    
    
60. NGUYEN AT, Shiao SL, McArthur HL
    Advances in Combining Radiation and Immunotherapy in Breast Cancer.
    Clin Breast Cancer. 2021 Mar 16. pii: S1526-8209(21)00062.
    PubMed         Abstract available
    
    
61. XU N, Zhou J, He X, Ye S, et al
    Radiomics Model for Evaluating the Level of Tumor-Infiltrating Lymphocytes in Breast Cancer Based on Dynamic Contrast-Enhanced MRI.
    Clin Breast Cancer. 2020 Dec 28. pii: S1526-8209(20)30336.
    PubMed         Abstract available
    
    
62. HALEY B, Batra K, Sahoo S, Froehlich T, et al
    A Phase I/Ib Trial of PD 0332991 (Palbociclib) and T-DM1 in HER2-Positive Advanced Breast Cancer After Trastuzumab and Taxane Therapy.
    Clin Breast Cancer. 2021 Mar 11. pii: S1526-8209(21)00060.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

63. LIM B, Potter DA, Salkeni MA, Silverman P, et al
    Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer.
    Clin Cancer Res. 2021 Apr 5. pii: 1078-0432.CCR-20-4131.
    PubMed         Abstract available
    
    
64. RUGO HS, Huppert L
    Answers are in the Blood: cfDNA to Enhance Precision Medicine for Breast Cancer.
    Clin Cancer Res. 2021 Apr 9. pii: 1078-0432.CCR-21-0353.
    PubMed         Abstract available
    
    

    
    Exp Cell Res

65. SHI X, Sun Y, Zhang Y, Wang W, et al
    MEX3A Promotes development and progression of breast cancer through regulation of PIK3CA.
    Exp Cell Res. 2021 Mar 31:112580. doi: 10.1016/j.yexcr.2021.112580.
    PubMed         Abstract available
    
    

    
    Gene

66. JANANI SK, Dhanabal SP, Sureshkumar R, Nikitha Upadhyayula SS, et al
    Guardian of genome on the tract: wild type p53-mdm2 complex inhibition in healing the breast cancer.
    Gene. 2021 Mar 31:145616. doi: 10.1016/j.gene.2021.145616.
    PubMed         Abstract available
    
    

    
    Histopathology

67. WILSHER MJ, Desai AJ, Pinder SE
    Low-grade adenosquamous carcinoma arising in association with a nipple adenoma.
    Histopathology. 2020;76:784-787.
    PubMed        
    
    
68. BERBEN L, Wildiers H, Marcelis L, Antoranz A, et al
    Computerised scoring protocol for identification and quantification of different immune cell populations in breast tumour regions by the use of QuPath software.
    Histopathology. 2020;77:79-91.
    PubMed         Abstract available
    
    

    
    Int J Cancer

69. APOSTOLOU P, Fostira F, Kouroussis C, Kalfakakou D, et al
    BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects.
    Int J Cancer. 2020;147:1334-1342.
    PubMed         Abstract available
    
    
70. YUAN S, Kar S, Vithayathil M, Carter P, et al
    Causal associations of thyroid function and dysfunction with overall, breast and thyroid cancer: A two-sample Mendelian randomization study.
    Int J Cancer. 2020;147:1895-1903.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

71. NAOUM GE, Taghian AG
    Complications May Outweigh the Benefits.
    Int J Radiat Oncol Biol Phys. 2020;108:1131-1132.
    PubMed        
    
    
72. ROYCE TJ, Marks LB
    Balancing the Benefits and Harms of Postmastectomy Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2020;108:1131.
    PubMed        
    
    
73. ZEIDAN YH, Poortmans P
    Don't Miss the Devil in the Details.
    Int J Radiat Oncol Biol Phys. 2020;108:1133.
    PubMed        
    
    
74. HANNOUN-LEVI JM, Montagne L, Sumodhee S, Schiappa R, et al
    APBI versus ultra APBI in the elderly with low-risk breast cancer: a comparative analysis of oncological outcome and late toxicity.
    Int J Radiat Oncol Biol Phys. 2021 Apr 5. pii: S0360-3016(21)00314.
    PubMed         Abstract available
    
    
75. MCCALL AR, Son CH
    Young and High Risk.
    Int J Radiat Oncol Biol Phys. 2020;108:1132-1133.
    PubMed        
    
    
76. MUTTER RW, Hepel JT
    Accelerated Partial Breast Radiation: Information on Dose, Volume, Fractionation, and Efficacy from Randomized Trials.
    Int J Radiat Oncol Biol Phys. 2020;108:1123-1128.
    PubMed        
    
    

    
    J Clin Oncol

77. JAGSI R, Griffith KA, Vicini F, Boike T, et al
    Toward Improving Patients' Experiences of Acute Toxicity From Breast Radiotherapy: Insights From the Analysis of Patient-Reported Outcomes in a Large Multicenter Cohort.
    J Clin Oncol. 2020;38:4019-4029.
    PubMed         Abstract available
    
    
78. TAIRA N, Sawaki M, Uemura Y, Saito T, et al
    Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer.
    J Clin Oncol. 2021 Apr 9:JCO2002751. doi: 10.1200/JCO.20.02751.
    PubMed         Abstract available
    
    
79. BEKELMAN JE, Gupta A, Fishman E, Debono D, et al
    Association Between a National Insurer's Pay-for-Performance Program for Oncology and Changes in Prescribing of Evidence-Based Cancer Drugs and Spending.
    J Clin Oncol. 2020;38:4055-4063.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

80. FEIGELSON HS, Bodelon C, Powers JD, Curtis RE, et al
    Body Mass Index and Risk of Second Cancer among Women with Breast Cancer.
    J Natl Cancer Inst. 2021 Apr 5. pii: 6210655. doi: 10.1093.
    PubMed         Abstract available
    
    
81. DEKKER J, Stege CAM, Versteeg KS
    Re: Deficit Accumulation Frailty Trajectories of Older Breast Cancer Survivors and Non-Cancer Controls: The Thinking and Living with Cancer Study.
    J Natl Cancer Inst. 2021 Apr 5. pii: 6210765. doi: 10.1093.
    PubMed        
    
    
82. YU KD, Ge JY, Liu XY, Mo M, et al
    Cyclophosphamide-free Adjuvant Chemotherapy for Ovarian Protection in Young Women with Breast Cancer: a Randomized Phase 3 Trial.
    J Natl Cancer Inst. 2021 Apr 2. pii: 6209077. doi: 10.1093.
    PubMed         Abstract available
    
    
83. RICHMAN IB, Long JB, Hoag JR, Upneja A, et al
    Comparative Effectiveness of Digital Breast Tomosynthesis for Breast Cancer Screening among Women 40-64 Years Old.
    J Natl Cancer Inst. 2021 Apr 3. pii: 6209735. doi: 10.1093.
    PubMed         Abstract available
    
    
84. LAMBERTINI M, Partridge AH
    Cyclophosphamide-free Adjuvant Chemotherapy for the Potential Prevention of Premature Ovarian Insufficiency and Infertility in Young Women with Breast Cancer.
    J Natl Cancer Inst. 2021 Apr 2. pii: 6209078. doi: 10.1093.
    PubMed        
    
    
85. HOFVIND S, Sebuodegard S, Botteri E
    Response to Zahl.
    J Natl Cancer Inst. 2020;112:1175.
    PubMed        
    
    
86. CHECK DK, Winn AN, Fergestrom N, Reeder-Hayes KE, et al
    Response to Strassels and Durham.
    J Natl Cancer Inst. 2020;112:1280.
    PubMed        
    
    
87. BLAES AH, Dang C
    Trastuzumab: Weighing the Benefits and the Risks.
    J Natl Cancer Inst. 2020;112:1181-1182.
    PubMed        
    
    
88. ANURAG M, Ellis MJ
    Response to Jezequel, Patsouris, Guette, et al.
    J Natl Cancer Inst. 2020;112:865.
    PubMed        
    
    
89. HELZLSOUER KJ, Reedy J
    Data Sharing for the Public Good.
    J Natl Cancer Inst. 2020;112:867-868.
    PubMed        
    
    

    
    J Pathol

90. LI S, Wu H, Huang X, Jian Y, et al
    BOP1 confers chemoresistance of triple-negative breast cancer by promoting CBP-mediated beta-catenin acetylation.
    J Pathol. 2021 Apr 2. doi: 10.1002/path.5676.
    PubMed         Abstract available
    
    

    
    Lancet

91. LOIBL S, Poortmans P, Morrow M, Denkert C, et al
    Breast cancer.
    Lancet. 2021 Apr 1. pii: S0140-6736(20)32381.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

92. DAVISON C, Morelli R, Knowlson C, McKechnie M, et al
    Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer.
    NPJ Breast Cancer. 2021;7:38.
    PubMed         Abstract available
    
    

    
    Oncogene

93. KIM ES, Nam SM, Song HK, Lee S, et al
    CCL8 mediates crosstalk between endothelial colony forming cells and triple-negative breast cancer cells through IL-8, aggravating invasion and tumorigenicity.
    Oncogene. 2021 Apr 8. pii: 10.1038/s41388-021-01758.
    PubMed         Abstract available
    
    

    
    Oncology (Williston Park)

94. FLORES-BALCAZAR CH, Castro-Alonso FJ, Hernandez-Barragan TP, Delgado-de la Mora J, et al
    The Role of Postmastectomy Radiotherapy in Locally Advanced Breast Cancer After Pathological Complete Response to Neoadjuvant Chemotherapy.
    Oncology (Williston Park). 2021;35:139-143.
    PubMed         Abstract available
    
    

    
    PLoS One

95. AGUIRRE-CAMACHO A, Hidalgo B, Gonzalez-Cuevas G
    Fear of breast cancer among young Spanish women: Factor structure and psychometric properties of the Champion breast cancer fear scale.
    PLoS One. 2021;16:e0249562.
    PubMed         Abstract available
    
    
96. KLINGEN TA, Chen Y, Aas H, Wik E, et al
    Fibulin-2 expression associates with vascular invasion and patient survival in breast cancer.
    PLoS One. 2021;16:e0249767.
    PubMed         Abstract available
    
    
97. MADUT A, Fuchsova V, Man H, Askar S, et al
    Increased prevalence of obstructive sleep apnea in women diagnosed with endometrial or breast cancer.
    PLoS One. 2021;16:e0249099.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

98. JONES MA
    CEST MRI pH Mapping of Tumor Acidity as a Predictor of Breast Cancer Metastatic Potential.
    Radiol Imaging Cancer. 2021;3:e219003.
    PubMed        
    
    
99. REGEN-TUERO HC, Ward RC, Sikov WM, Littrup PJ, et al
    Cryoablation and Immunotherapy for Breast Cancer: Overview and Rationale for Combined Therapy.
    Radiol Imaging Cancer. 2021;3:e200134.
    PubMed         Abstract available
    
    

    
    Radiology

100. MANN RM
     Tomosynthesis Is Taking Small Steps to Become the Standard for Breast Cancer Screening.
     Radiology. 2021 Apr 6:210153. doi: 10.1148/radiol.2021210153.
     PubMed        
     
     
101. JOHNSON K, Lang K, Ikeda DM, Akesson A, et al
     Interval Breast Cancer Rates and Tumor Characteristics in the Prospective Population-based Malmo Breast Tomosynthesis Screening Trial.
     Radiology. 2021 Apr 6:204106. doi: 10.1148/radiol.2021204106.
     PubMed         Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: